Abstract
Febrile neutropenia remains an important complication of treatment with cytotoxic chemotherapy. It is often the first and sometimes the only sign or symptom of infection in this vulnerable patient population. Urgent and appropriate evaluation and treatment are imperative because delay in initiating appropriate antibiotic therapy may be life threatening. Selection of antibiotics should be based on the patient's symptoms, previous culture data, and institutional antibiograms. Ongoing therapy should be guided by culture and clinical data. Antimicrobial resistance is of great concern, particularly in this population, so careful attention to antibiotic selection and duration is needed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 19-24 |
| Number of pages | 6 |
| Journal | Journal of Oncology Practice |
| Volume | 15 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Oncology(nursing)
- Health Policy
Cite this
Optimal Management of Neutropenic Fever in Patients With Cancer. / Zimmer, Andrea J.; Freifeld, Alison Gail.
In: Journal of Oncology Practice, Vol. 15, No. 1, 01.01.2019, p. 19-24.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Optimal Management of Neutropenic Fever in Patients With Cancer
AU - Zimmer, Andrea J.
AU - Freifeld, Alison Gail
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Febrile neutropenia remains an important complication of treatment with cytotoxic chemotherapy. It is often the first and sometimes the only sign or symptom of infection in this vulnerable patient population. Urgent and appropriate evaluation and treatment are imperative because delay in initiating appropriate antibiotic therapy may be life threatening. Selection of antibiotics should be based on the patient's symptoms, previous culture data, and institutional antibiograms. Ongoing therapy should be guided by culture and clinical data. Antimicrobial resistance is of great concern, particularly in this population, so careful attention to antibiotic selection and duration is needed.
AB - Febrile neutropenia remains an important complication of treatment with cytotoxic chemotherapy. It is often the first and sometimes the only sign or symptom of infection in this vulnerable patient population. Urgent and appropriate evaluation and treatment are imperative because delay in initiating appropriate antibiotic therapy may be life threatening. Selection of antibiotics should be based on the patient's symptoms, previous culture data, and institutional antibiograms. Ongoing therapy should be guided by culture and clinical data. Antimicrobial resistance is of great concern, particularly in this population, so careful attention to antibiotic selection and duration is needed.
UR - http://www.scopus.com/inward/record.url?scp=85059829136&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059829136&partnerID=8YFLogxK
U2 - 10.1200/JOP.18.00269
DO - 10.1200/JOP.18.00269
M3 - Article
VL - 15
SP - 19
EP - 24
JO - Journal of Oncology Practice
JF - Journal of Oncology Practice
SN - 1554-7477
IS - 1
ER -